Choose your location:

Go to the global Ipsen site

Choose your language

Contact us

Press Releases


19 results

May 4, 2022

Health Canada approves Ipsen’s CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory or Ineligible Differentiated Thyroid Cancer

Canada

October 20, 2021

Health Canada approves Ipsen’s CABOMETYX® (cabozantinib) in combination with OPDIVO® (nivolumab) as a first-line treatment for adults with advanced or metastatic renal cell carcinoma

Canada

March 16, 2021

Health Canada Approves INCRELEX®, First and Only Recombinant Human Insulin-like Growth Factor-1 (IGF-1) Therapy in Canada for the Treatment of Severe Growth Failure Associated with Ultra-Rare Condition in Children and Adolescents

Canada

May 4, 2020

Ipsen enters into an option agreement with IRICoR and Université de Montréal for a discovery-stage oncology program

Canada

Ipsen-IRICOR-Press-Release-010520-ENGLISH-FINAL.pdf
January 7, 2020

Ipsen Announces the Availability of the Newly Designed Delivery System for Somatuline® Autogel® (lanreotide injection)

Canada

Somatuline-News-Release-FINAL-1.pdf
November 12, 2019

Health Canada approves CABOMETYXTM (cabozantinib) Giving Physicians and Adult Patients a New Second-Line Option in the Fight Against Advanced Hepatocellular Carcinoma

Canada

HCC-2L-Press-Release-FINAL.pdf
October 15, 2019

Health Canada Approves Ipsen’s CABOMETYX™ (cabozantinib) for the First-Line Treatment of Adults with Advanced Renal Cell Carcinoma

Canada

Cabometyx-RCC-1st-Line-NOC-Press-Release-ENGLISH-FINAL-.pdf
October 16, 2018

Health Canada approves XERMELO™ (telotristat ethyl) for the treatment of adult patients suffering from refractory carcinoid syndrome diarrhea

Canada

XERMELO-NOC-Press-Release-English-FINAL-FOR-WEBSITE.pdf
October 11, 2018

Ipsen Canada Appoints Ed Dybka as General Manager

Canada

Ipsen-Canada-Ed-Dybka-General-Manager-FINAL.pdf
September 18, 2018

Health Canada Approves Ipsen’s CABOMETYX™ (cabozantinib) Giving Physicians and Patients a Novel Second-Line Option in the Fight Against Advanced Renal Cell Carcinoma

Canada

Cabozantinib-NOC-Press-Release-English.pdf
March 15, 2018

Ipsen Announces Health Canada Approval of DYSPORT THERAPEUTIC™ (abobotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Adults

Canada

Canada_Dysport-Therapeutic-ALL-Press-Release_EN_March-14-2018_FINAL.pdf
February 13, 2018

Health Canada approves Ipsen’s Somatuline® Autogel® for the treatment of carcinoid syndrome in adult patients with neuroendocrine tumours (NETs)

Canada

Somatuline-NOC-News-Release-English.pdf
January 9, 2018

Ipsen Biopharmaceuticals Canada Inc. Announces Health Canada Approval of DYSPORT THERAPEUTIC™ (abobotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Children Aged Two and Older

Canada

Canada_Press-Release_Dysport-Therapeutic_PLL.pdf
September 5, 2017

Ipsen Biopharmaceuticals Canada Names Paul Reider Country Manager and Joins Innovative Medicines Canada to Drive Development and Delivery of Key Therapies

Canada

Canada-IMC-Membership-and-Country-Manager-Announcement1.pdf
December 22, 2016

Ipsen Amends Licensing Agreement With Exelixis To Commercialize And Develop Cabozantinib In Canada

Canada

Ipsen-Cabozantinib-Press-Release_ENGLISH-FINAL-DEC-221.pdf
May 23, 2016

Ipsen pledges $10,000 to Red Cross wild fire relief in Alberta

Canada

Ipsen-Red-Cross-Donation_FINAL_May-2016_ENG.pdf
October 14, 2015

Ipsen Grand Opening

Canada

Grand-Opening-News-Release-English-October-14_FINAL.pdf
June 15, 2015

Health Canada Approves Somatuline Autogel for the treatment of enteropancreatic neuroendocrine tumours (NETs)

Canada

CAN_PR_SOMA-Approval-07-08-15_EN.pdf
April 15, 2015

Ipsen Biopharmaceuticals expands to Canada

Canada

Ipsen-Canada-Press-Release-FINAL-ENGLISH.pdf
©2024 Ipsen Biopharmaceuticals, Inc. All rights reserved. June 2023 CR-CA-000013